ARLINGTON, Va., May 30, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that its management team plans to present at the 44th Annual William Blair Growth Stock Conference on Wednesday, June 5, 2024, beginning at 11:00 am ET / 10:00 am CT.
The live webcast and replay of the event will be available at ir.priviahealth.com/news-and-events/events-and-presentations.
About Privia Health
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Privia Health’s platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Contact
Robert Borchert
SVP, Investor & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
817.783.4841
| Last Trade: | US$23.11 |
| Daily Change: | 1.30 5.96 |
| Daily Volume: | 559,343 |
| Market Cap: | US$2.840B |
August 07, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
